Traverse 2024 Testosterone. The results, from the phase 4 traverse study, showed a negligible difference in cv events among men aged 45 to 80 years with hypogonadism who were treated with. Cardiovascular safety of testosterone therapy for older men lancet diabetes endocrinol.

After reviewing the complex recent history and controversies surrounding testosterone therapy, dr. A total of 5,204 patients were.